Ratings Natera, Inc.

Equities

NTRA

US6323071042

Real-time Estimate Cboe BZX Other stock markets 12:18:02 2024-04-19 pm EDT			5-day change	1st Jan Change
84.5 ^USD	-3.19%		-10.62%	+34.79%

Apr. 18	Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	MT
Apr. 18	Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company is in a robust financial situation considering its net cash and margin position.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NATERA, INC.	+34.79%	10.54B		C-
CVS HEALTH CORPORATION	-11.61%	87.46B		B-
HCA HEALTHCARE, INC.	+12.14%	78.56B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.85%	29.37B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.62%	16.78B		B
FRESENIUS SE & CO. KGAA	-4.17%	16.01B		A-
QUEST DIAGNOSTICS INCORPORATED	-6.98%	13.98B		A-
EUROFINS SCIENTIFIC SE	+0.92%	12.31B		A-
PURE HEALTH HOLDING	-30.35%	12.07B	-	-
DAVITA INC.	+22.31%	11.06B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes